Dr. Joanne Lorraine Blum M.D.
Oncologist | Medical Oncology
3410 Worth St Dallas TX, 75246About
Joanne L. Blum, M.D., Ph.D., FACP specializes in medical oncology and hematology. She is a Diplomate of the American Board of Internal Medicine with subspecialty certifications in medical oncology and ...
Education and Training
Univ of Md Sch of Med, Baltimore Md 1979
University of Maryland School of Medicine 1979
Board Certification
Internal MedicineAmerican Board of Internal MedicineABIM- Medical Oncology
Provider Details
Expert Publications
Data provided by the National Library of Medicine- Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma.
- Family environments of women seeking BRCA1/BRCA2 genetic mutation testing: an exploratory analysis.
- Capecitabine/Taxane combination therapy: evolving clinical utility in breast cancer.
- Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
- Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers.
- Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers.
- Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
- Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
- Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials.
- Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers.
- Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer.
- Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
- A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.
- Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
- Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers.
Awards
- 2005-2011 Texas Super Doctors
Treatments
- Breast Cancer, Cancer Genetics, Hereditary Cancer
- Anemia
- Osteoporosis
- Skin Cancer
- Breast Cancer
- Lung Cancer
- Acute Myeloid Leukemia (aml)
- Lymphoma
- Ovarian Cancer
- Multiple Myeloma
- Leukemia
- Dermal Aesthetics
- Extra Corporeal Shockwave Therapy
Dr. Joanne Lorraine Blum M.D.'s Practice location
Dr. Joanne Lorraine Blum M.D.'s reviews
Write ReviewPatient Experience with Dr. Blum
Recommended Articles
- Why Is Hereditary Ovarian Cancer Risk on the Rise in India?
Ovarian cancer is one of the more serious cancers which can affect women. It is the seventh most common cause of cancer in women, affecting one in twenty-eight women. The symptoms can be difficult to detect, as they mimic the effects of other, less dangerous diseases. When caught early, most women...
- Understanding a Breast Cancer Biopsy Report
When a physician suspects that a patient may have breast cancer, they will likely call for a biopsy to be done in order to make an exact diagnosis and begin the prognosis stage. In order to do a biopsy tissue, cells, or lumps must be removed from the breast and sent to the lab in order to be tested....
- Survivors and Soulmates
“Every 3 minutes, a woman learns she has breast cancer. She is a mother, a daughter, a sister, a friend. I am that woman. Every 13 minutes, a woman dies of the disease. I will not be that woman. I will survive.” This is a message by writer and fashion stylist Meredith Gray in the documentary...
- Wigs During Cancer Treatment: To Wear or Not To Wear?
Many cancer patients have to go through round after round of chemotherapy treatment during their recovery program. One of the most common side effects of the radiation is loss of hair, especially on the head. This can potentially lead to a lot of issues for cancer patients in terms of their...
- Low-Dose Aspirin May Cut Ovarian Cancer Risk
Aspirin, a nonsteroidal anti-inflammatory drug, can help with many health problems. It can reduce fever, ease pain, and even prevent a heart attack or stroke. For some time now researchers have looked into the connection between aspirin and cancer prevention. ...
- $5.8 Million Grant Given to Develop New Immunotherapy for Ovarian Cancer
Ovarian cancer cells can be extremely tricky to get rid of, which makes treatment often expensive and prolonged. Researchers at the University of California San Diego recently received a 5.8-million-dollar grant from the state to develop a new form of immunotherapy for ovarian cancer.The StudyThe...
Nearby Providers
- Dr. Thomas Hutson DO,PHARMD3535 Worth St Dallas TX 75246
- Dr. SARA ROBINSON M.D.3500 Gaston Ave Dallas TX 75246
- Dr. Houston Eccleston Holmes M.D.3535 Worth St Dallas TX 75246
- Dr. Edward D Agura M.D.3535 Worth St Dallas TX 75246
- Dr. Luis Pineiro MD3409 Worth St Dallas TX 75246
- Dr. Barry Neal Wilcox M.D.3535 Worth St Dallas TX 75246